SEC 13F Intelligence

Managers / Q3 2020 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$137M
Q3 2020
Positions
113
Filings on Record
30
2019–present window
Filed
Nov 16, 2020
original filing

Summary

Highvista Strategies LLC reported $137M in U.S.-listed holdings across 113 positions for Q3 2020.

The portfolio is heavily concentrated: DELL alone accounts for 33.6% of reported value.

Compared with Q2 2020, the fund opened 47 new positions and exited 34.

Portfolio Metrics

Turnover
+19.9%
vs prior filed quarter
Top-10 Concentration
+68.5%
share of reported value
Largest Position
+33.6%
Dell Technologies
New / Exited
47 / 34
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 72.1%Other: 15.6%ADR: 9.8%ETP: 2.5%REIT: 0.0%
  • Common Stock · 72.1% · $99M
  • Other · 15.6% · $21M
  • ADR · 9.8% · $13M
  • ETP · 2.5% · $3M
  • REIT · 0.0% · $62,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LIVONGO HEALTH INCNEW+24.9K24.9K+$3M$3M
DELPHI TECHNOLOGIES PLNEW+189.1K189.1K+$3M$3M
MXIMMAXIM INTEGRATED PRODS INCNEW+42.6K42.6K+$3M$3M
GRUBHUB INCNEW+27.9K27.9K+$2M$2M
IMMUIMMUNOMEDICS INCNEW+11.7K11.7K+$997,000$997,000
INVITAE CORPNEW+15.4K15.4K+$668,000$668,000
TCE2CELLDEX THERAPEUTICS INC NEWNEW+44.8K44.8K+$665,000$665,000
SUTRO BIOPHARMA INCNEW+64.7K64.7K+$651,000$651,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C33.57%$46M680.6K
2BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS7.67%$11M35.8K
3WILLIS TOWERS WATSON PLC LTDSHS6.25%$9M41.1K
4AMTTD AMERITRADE HLDG CORPhistory →COM5.21%$7M182.6K
5TIFEURTIFFANY & CO NEWhistory →COM4.31%$6M51.1K
6LIVONGO HEALTH INCCOM2.54%$3M24.9K
7DELPHI TECHNOLOGIES PLSHS2.30%$3M189.1K
8FITEURFITBIT INChistory →CL A2.29%$3M451.0K
9WRIGHT MED GROUP N VORD SHS2.18%$3M98.0K
10ACIAACACIA COMMUNICATIONS INChistory →COM2.18%$3M44.4K
11ISHARES TRMSCI INDIA ETF · MSCI INDIA SM CP2.14%$3M84.7K
12MXIMMAXIM INTEGRATED PRODS INChistory →COM2.10%$3M42.6K
13GRUBHUB INCCOM1.47%$2M27.9K
14GNWGENWORTH FINL INChistory →COM CL A1.41%$2M578.0K
15IMMUIMMUNOMEDICS INCCOM0.73%$997,00011.7K
16TSMTAIWAN SEMICONDUCTOR MFG LTDSPONSORED ADS0.59%$811,00010.0K
17KURAKURA ONCOLOGY INCCOM0.55%$761,00024.8K
18ZYMEUSDZYMEWORKS INCCOM0.55%$760,00016.3K
19TREURTRILLIUM THERAPEUTICS INCCOM NEW0.54%$744,00052.3K
201K0IGM BIOSCIENCES INCCOM0.51%$695,0009.4K
21INVITAE CORPCOM0.49%$668,00015.4K
22TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.48%$665,00044.8K
23MYOKEURMYOKARDIA INCCOM0.48%$652,0004.8K
24SUTRO BIOPHARMA INCCOM0.47%$651,00064.7K
25IMVTIMMUNOVANT INCCOM0.46%$630,00017.9K
26FORMA THERAPEUTICS HLDGS INCSHS0.45%$614,00012.3K
27KODKODIAK SCIENCES INCCOM0.44%$598,00010.1K
28TGTXTG THERAPEUTICS INCCOM0.42%$576,00021.5K
29STOKSTOKE THERAPEUTICS INCCOM0.42%$572,00017.1K
30IM8NINSMED INCCOM PAR $.010.41%$567,00017.6K
31MRTXEURMIRATI THERAPEUTICS INCCOM0.41%$565,0003.4K
32DNLIDENALI THERAPEUTICS INCCOM0.41%$564,00015.7K
33SG7SAGE THERAPEUTICS INCCOM0.41%$561,0009.2K
34ARNAEURARENA PHARMACEUTICALS INCCOM NEW0.40%$555,0007.4K
35XNCRXENCOR INCCOM0.40%$555,00014.3K
36DBCINVESCO DB COMMDY INDX TRCKUNIT0.40%$554,00042.4K
37IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.40%$554,00016.8K
38FATEFATE THERAPEUTICS INCCOM0.40%$552,00013.8K
39SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.40%$547,00011.5K
40DCPHEURDECIPHERA PHARMACEUTICALS INCOM0.40%$543,00010.6K
41OPHTEURIVERIC BIO INCCOM0.39%$541,00096.0K
42ARGXARGENX SESPONSORED ADR0.39%$540,0002.1K
43MBTGBPMOBILE TELESYSTEMS PJSCSPONSORED ADR0.38%$526,00060.2K
44MOLECULAR TEMPLATES INCCOM0.38%$517,00047.4K
45CCXIEURCHEMOCENTRYX INCCOM0.38%$515,0009.4K
46ACADACADIA PHARMACEUTICALS INCCOM0.37%$513,00012.4K
47ASCENDIS PHARMA A/SSPONSORED ADR0.37%$510,0003.3K
48BDTXBLACK DIAMOND THERAPEUTICS ICOM0.36%$496,00016.4K
49NVONOVO-NORDISK A SADR0.36%$493,0007.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.